Fa-Ying Zhou

Fa-Ying Zhou

Auto-generated profile, based on publicly available information

Fa-Ying Zhou

Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
ZCZu-Qi Chen
Zu-Qi Chen
MWMeng-Ting Wang
Meng-Ting Wang
CTCheng-Rong Tan
Cheng-Rong Tan
SHShan Huang
Shan Huang
FZFa-Ying Zhou
Fa-Ying Zhou
YWYanjiang Wang
Yanjiang Wang
Background: A disintegrin and metalloproteinase 17 (ADAM-17) has multiple pathophysiological functions in Alzheimer's disease (AD). However, the clinical relevance of ADAM-17 in AD is not clear yet. Objective: This study aims to investigate the levels of circulating ADAM-17 and their association with AD. Methods: This cross-sectional study recruited 40 normal cognition (NC) participants and 36 AD patients. Plasma ADAM-17 and biomarkers of neurodegeneration were determined. The association of plasma ADAM-17 with cognitive functions and biomarkers of neurodegeneration was analyzed. Results: Plasma ADAM-17 levels were elevated in AD patients in comparison with NC subjects. Plasma ADAM-17 was positively associated with Clinical Dementia Rating (CDR) scores, but negatively associated with the Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Plasma ADAM-17 levels were positively associated with the levels of Aβ 40 , Aβ 42 , and p-Tau181. Conclusions: These findings suggest a link between ADAM-17 and the pathogenesis of AD from a clinical perspective.